Fig. 5

MiR-223 infusion remarkably inhibited the development of aGvHD. Recipient BABL/6 mice were irradiated (8.0 Gy) and intravenously injected with C57BL/6j bone marrow cells plus splenocytes. The survival rate of miR-223 group was further improved compared with the other groups (a). The clinical aGvHD scores of miR-223 group of mice were significant alleviated compared with the scores of the aGvHD and NC groups of mice (b). For the representative pathologic changes on day 14, miR-223 infusion dramatically decreased lymphocyte infiltration in the GvHD target tissues, including the spleen, liver, and intestine (c). The inflammatory cytokine level (IFN-γ, IL-17a, and TNF-α) showed significant decline in the blood serum of the miR-223 group compared with that of the aGvHD or NC (d). Data were presented as mean ± SEM. Measured in three independent experiments, n = 5 per group. *P < 0.05, **P < 0.01, ***P < 0.001